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Abstract: Protein kinase type C-ε (PKCε) plays important roles in the sensitization of primary afferent
nociceptors, such as ion channel phosphorylation, that in turn promotes mechanical hyperalgesia
and pain chronification. In these neurons, PKCε is modulated through the local release of mediators
by the surrounding Schwann cells (SCs). The progesterone metabolite allopregnanolone (ALLO) is
endogenously synthesized by SCs, whereas it has proven to be a crucial mediator of neuron-glia
interaction in peripheral nerve fibers. Biomolecular and pharmacological studies on rat primary
SCs and dorsal root ganglia (DRG) neuronal cultures were aimed at investigating the hypothesis
that ALLO modulates neuronal PKCε, playing a role in peripheral nociception. We found that SCs
tonically release ALLO, which, in turn, autocrinally upregulated the synthesis of the growth factor
brain-derived neurotrophic factor (BDNF). Subsequently, glial BDNF paracrinally activates PKCε via
trkB in DRG sensory neurons. Herein, we report a novel mechanism of SCs-neuron cross-talk in the
peripheral nervous system, highlighting a key role of ALLO and BDNF in nociceptor sensitization.
These findings emphasize promising targets for inhibiting the development and chronification of
neuropathic pain.
Keywords: neuro-glia interaction; neuropathic pain; hyperalgesia; dorsal root ganglia;
neuroactive steroid
1. Introduction
Schwann cells (SCs) are the main glial cells of the peripheral nervous system (PNS). Myelinating
SCs form the myelin sheath, which electrically isolates axons and allows saltatory conduction of
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the action potentials. Non-myelinating SCs surround unmyelinated fibers to form Remak bundles,
where SCs ensheath multiple small-caliber axons, isolating one from another [1,2]. The majority
of unmyelinated axons serve sensory function associated with thermoception and nociception.
Besides these structural purposes, SCs cross-interact with neurons, specifically with whole axons,
regulating their physiological functions. A plethora of mediators is produced and/or released by
SCs, thus regulating the neuron-glial interaction, including neuropeptides, cytokines, growth factors,
integrins, neuregulins, neurotransmitters and neuroactive steroids [3–7].
The progesterone metabolite 5α-pregnan-3α-ol-20-one, named tetrahydroprogesterone or
allopregnanolone (ALLO), is the most important neuroactive steroid, targeting both neurons and
glial cells in the PNS [8]. ALLO is produced by SCs, since these cells possess the biosynthetic
enzymatic complex [9–11]. In the PNS, ALLO participates in the control of myelination, nerve
regeneration [9,12–14] and also nociception [15]. ALLO capacity to modulate nociceptive pathways has
long been ascribed to its allosteric activation of the GABA type A (GABAA) receptor, thus potentiating
its inhibitory role, at least in central nervous system (CNS) synapses [16].
The ε isoform of protein kinases C (PKCε) possesses several roles in the function of the nervous
system [17,18], and in particular in pain modulation. Rather than simply inducing an acute increase of
nociceptor excitability, PKCε is crucial in establishing a long-term sensitization, also termed hyperalgesic
priming [19,20]. According to this view, PKCε acts by phosphorylating several ion channels, to increase
neuronal excitability. Indeed, PKCε lowers the heat activation threshold of TRPV1 [21,22], decreases
GABAA receptor inhibitory effect [23–25] and upregulates Nav1.8 expression [26]. Importantly,
PKCε reduces GABAA receptor sensitivity to ALLO [27]. Very preliminary data showed that ALLO
upregulates PKCε expression in peripheral neurons via SC activation [28], although the mechanism
behind this modulation is still unclear. Altogether, the cross interaction between ALLO, GABAA and
PKCε rises the hypothesis of a complex modulation of peripheral pain pathways.
Based on these lines of evidence we tested the hypothesis that PKCε in peripheral sensory
neurons may be locally modulated by SCs. Using a combination of biomolecular and pharmacological
approaches we studied rat primary SCs and dorsal root ganglia (DRG) neurons in vitro, investigating
whether PKCε in neurons is regulated by ALLO and/or other factors released by SCs. Our data
highlight a novel mechanism through which peripheral glial-to-neuron cross-talk autocrinally and
paracrinally controls PKCε and likely neuropathic pain onset and chronification.
2. Material and Methods
2.1. Animals
All experiments involved newborn and adult male Sprague–Dawley (Charles River) rats and
were performed in accordance with current European rules concerning care and use of animals
(Council Directive 2010/63/EU of the European parliament and the Council of 22 September 2010
on the protection of animal used for scientific purposes) and according to 3R’s guidelines. Animal
authorization was: project number 478/2015-PR, approved the 3rd June 2015.
2.2. Sensory Neurons and SCs Primary Cultures
Primary sensory neurons were obtained from DRG, as previously described [14,29], with minor
modification. Briefly, DRG were harvested and dissociated for 40 min in Ham’s F12 medium
(Life Technologies Italia, Monza, Italy), containing 0.125% (w/v) collagenase Type IV (Worthington
Biochemical, Lakewood, NJ, USA), followed by 30 min digestion with 0.25% (w/v) trypsin (Worthington
Biochemical) and filtration with 100µm membrane (BD Biosciences, Milan, Italy). Cells were suspended
in Ham’s F12 and purified on a gradient of 20% (w/v) bovine serum albumin (BSA; Sigma-Aldrich, Milan,
Italy). The dissociated neurons were suspended in Bottenstein and Sato’s medium with minor changes
[BSM; F12 medium plus N2 (100 µM putrescine, 30 nM sodium selenite, 20 nM progesterone, 0.1 mg/mL
BSA, 1.3 mM transferrin, 10 pM insulin) and nerve growth factor 50 ng/mL, all Sigma-Aldrich] plus
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10 µM arabinoside C (AraC; Sigma-Aldrich). A cell suspension (1.5 × 104) of neurons was seeded
on a 35 mm petri dish coated with 2 µg/mL poli-L-lysine and 2 µg/mL laminin (Sigma-Aldrich).
DRG neurons were characterized by immunofluorescence for neurofilament of 200 kDa (NF200,
Sigma-Aldrich), as described [14,29]. SCs cultures were obtained as previously described [14,30].
Sciatic nerves were digested with 1% collagenase and 0.25% trypsin (Sigma-Aldrich), then mechanically
dissociated, filtered through a 100 µm filter (BD Biosciences) and centrifuged 5 min at 900 rpm. Pellets
were suspended in Dulbecco’s modified Eagle’s medium (DMEM, Serotec, Oxford, UK) plus 10% fetal
calf serum (FCS; Life Technologies Italia) and plated on 35 mm Petri dishes. After 24 h, the medium was
supplemented with 10 µM Ara-C (Sigma-Aldrich). Medium was then changed with DMEM-FCS 10%
plus 10 µM forskolin (Sigma-Aldrich) and 200 µg/mL bovine pituitary extract (BPE; Life Technologies
Italia). Cells became confluent in 10 days. Immunopanning for final purification was carried out
incubating the cells 30 min with mouse anti rat Thy1.1 antibody (Serotec, Italy), followed by 500 µL of
baby rabbit complement (Cedarlane, Burlington, NJ, USA). Cell suspension (6 × 104 cells) was seeded
on 35 mm petri dishes, in presence of 2 µM forskolin. At the third in vitro passage, SCs were treated
for 48 h with 4 µM forskolin, then used for different assays. SC purity (more than 98%) was tested
with a specific antibody against glycoprotein P0 [30]. Phase-contrast images of DRG neurons and SCs
in vitro cultures are provided in Supplementary Figure S2
2.3. Pharmacological Treatments
The desired concentration of each substance was achieved by dilution from stock into the
culture medium. Substances used were: ALLO (Sigma-Aldrich), human recombinant brain-derived
neurotrophic factor (BDNF; Millipore, Darmstadt, Germany) and cyclotraxin B (CYCLO; generous
gift by Dr. Michel M.M. Verheij). ALLO 1 µM concentration was used according to our previous
experiments [28] and in order to exclude any possible involvement of GABA-mediated endogenous
activity. Differentiated SCs primary cultures were treated for the indicated time after overnight serum
free condition, while DRG neurons’ primary culture was treated for the indicated time after 24 h
N2-free condition. Conditioned experiments on DRG neurons were performed comparing DRG
neurons treated with ALLO-exposed (24 h) SC’s conditioned medium (named CM + ALLO) with DRG
neurons treated with vehicle-exposed (ethanol; 24 h) SC conditioned medium (named CM CTRL).
Furthermore, in some experiments DRG neurons were treated with ALLO plus CYCLO-exposed (24 h)
SC conditioned medium (named CM + ALLO + CYCLO).
2.4. RNA Extraction and qRT-PCR
RNA samples from DRG neurons and SCs cultures were extracted using TrizolTM (Life Technologies
Italia) according to the manufacturer’s protocol, and quantified with NanoDrop2000 (Thermo
Fisher Scientific, Monza, Italy). Pure RNA was obtained after DNAse treatment with a specific
kit (Sigma-Aldrich). One µg of RNA was reverse-transcribed to cDNA using iScript™ Reverse
Transcription Supermix for RT-qPCR (Bio-Rad, Segrate, Milan, Italy). Primers were designed by
PrimerBlast software (NIH, Bethesda, MD, USA). Primer sequences for PKCε and the housekeeper
genes α-tubulin, 18s-rRNA and β2-microglobulin are reported in the Table 1. Ten ng of cDNA for
each sample were used for Real Time PCR. qRT-PCR was performed by measuring the incorporation
of EVA Green dye (Bio-Rad) with a CFX 96 Real Time System-C1000 touch thermal cycler (Bio-Rad).
Data analysis was performed using the CFX Manager 2.0 software (Bio-Rad). The threshold cycle
number (Ct) values of both the calibrator and the samples of interest were normalized to the geometric
mean of Ct of the endogenous housekeeping genes. Data analysis was performed according to the Pfaff
method and results are expressed as relative expression, normalized on the mean of housekeeper genes.
As calibrator we used the RNA obtained from control samples. BDNF and trkB mRNA expression was
analyzed by TaqMan qRT-PCR instrument (CFX384 real time system, Bio-Rad) using the iScriptTM
one-step RT-PCR kit (Bio-Rad), as previously described [31]. Briefly, samples were run in 384 wells
formats in triplicate as multiplexed reactions. Data were analyzed with the comparative threshold
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cycle (∆∆Ct) method using β-actin as reference gene. The primer efficiencies were experimentally set
up for each couple of primers. Primers and probes for BDNF, trkB and β-actin (Eurofins MWG-Operon)
are reported in Table 1.
Table 1. Sequences of primers used in the qRT-PCR.
Primer Name Forward Primer 5′–3′ Reverse Primer 5′–3′ Probe (When Applicable)
PKCε CCCCTTGTGACCAGGAACTA AGCTGGCCATCAGTAGACGA
BDNF AAGTCTGCATTACATTCCTCGA GTTTTCTGAAAGAGGGACAGTTTAT GATCAGGTCAGACAAGTCAAGG
trkB GTGGATTCCGGCTTAAAGTTTG GATCAGGTCAGACAAGTCAAGG CCTGCGGCACATCAATTTCACTCG
α-tubulin TCGCGCTGTAAGAAGCAACACC ATGGAGATGCACTCACGATGGT
18s CTGCCCTATCAACTTTCGATGGTAG CCGTTTCTCAGGCTCCCTCTC
β2-microglobulin ACATACGCCTGCAGAGTTAAGC TGCTTGATCACATGTCTCGATCCC
β-actin CACTTTCTACAATGAGCTGCG CTGGATGGCTACGTACATGG TCTGGGTCATCTTTTCACGGTTGGC
2.5. Immunofluorescence (IFL)
Nerves were explanted and de-sheeted, then fixed in 4% paraformaldehyde (PFA, Sigma-Aldrich),
included in OCT (Sakura, Leiden, The Netherlands) and cut in cross sections. For teased fibers, a slight
digestion was performed incubating nerves fragments in collagenase IV for 45 min, before fixing in
4% PFA (Sigma-Aldrich). Cells were fixed in 4% PFA and processed for immunostaining. Primary
antibodies used in these experiments were the following: rabbit anti PKCε 1:200 (Abcam), rabbit anti
phospho S729 PKCε 1:200 (Abcam), mouse anti SMI31 1:500 (Biolegend, San Diego, CA, USA), mouse
anti SMI32 1:500 (Biolegend), rabbit anti trkB 1:200 (Santa Cruz Biotechnology, Dallas, TX, USA)
and fluoromyelin 1:150 (Thermo Fisher Scientific). After washing, slides and nerves were
mounted using VectashieldTM (Vector Laboratories, Burlingame, CA, USA) and nuclei stained with
4,6-diamidino-2-phenylindole (DAPI). Confocal microscopy was carried out using a Zeiss LSM 900
Airyscan 2 (Zeiss, Gottingen, Germany) and images were processed with Image Pro-Plus 6.0 (Media
Cybernetics, Bethesda, MA, USA). Controls for specificity included a lack of primary antibody.
2.6. Western Blotting
Protein samples were extracted in lysis buffer (PBS, 1% Nonidet P-40 and 1 mM EDTA; all by
Sigma-Aldrich) containing a cocktail of protease inhibitors (Sigma-Aldrich). Samples were heated
for 20 min at 55 ◦C to denature secondary structures, then 15 µg were loaded onto an SDS-PAGE
gel (Criterion TGX; Bio-Rad) and run at 200 V for 40 min in running buffer. Gels were electroblotted
to PVDF membrane (GE Healthcare, Milan, Italy). Membranes were blocked with 10% not-fat
dry milk (Bio-Rad) in TBS before incubation with the primary antibody against BDNF diluted in
the blocking solution (1:500, Santa Cruz Biotechnology). Results were standardized using β-actin
(1:10,000, Sigma-Aldrich) as reference. Membranes were incubated with appropriated HRP-conjugated
secondary antibodies (Cell Signaling Technology Inc., Milan, Italy). Immunocomplexes were revealed
by enhanced chemiluminescence (GE Healthcare), visualized using the Chemidoc MP Imaging System
(Bio-Rad) and analyzed by the Image Lab software (Bio-Rad).
2.7. Quantitative Analysis of ALLO by Using Liquid Chromatography Tandem Mass Spectrometry Analysis
(LC-MS/MS)
ALLO from medium and cells was extracted according to Caruso et al. [32] with minor modification.
Briefly, the 13C-pregnenolone (PREG-20,21-13C2; 10 ng/sample), as internal standard, was added to
the samples. Purification was performed using a C18 cartridges (Discovery DSC-18, 500 mg, Supelco,
Milano, Italy). The steroid fraction was eluted with methanol (5 mL) and the organic residue was
reconstituted with methanol:water (1:1) before the injection in a RP-C18 analytical column (Hypersil
GOLD, Thermo Fisher Scientific Inc., Rodano, Italy; 3 µm, 100 mm × 3 mm ID). The high-performance
liquid chromatograph (Surveyor LC Pump Plus, Thermo Fisher Scientific Inc.) was coupled to a linear
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ion trap mass spectrometer (LC/MS; LTQ, Fisher Scientific Co, Hampton, New Hampshire, USA).
Atmospheric pressure chemical ionization source operating in the positive ion mode was used as
ion source. ALLO was identified comparing both the retention time and the tandem mass (MS/MS)
spectrum with that of the reference pure compound. The quantitative analyses were done monitoring
specific ions (multiple reacting monitoring, MRM) selected in the MS/MS spectrum obtained by collision
of precursor ions and by means of calibration curves, using the 13C-pregnenolone as internal standard.
2.8. ELISA Assay
Serum free medium were collected from SCs culture after 24 h of treatment with ALLO 1 µM,
and concentrated using Amicon ultra centrifugal filter of 3 kDa (Millipore). ELISA was done following
the manufacturer’s instruction (Raybiotech). BDNF concentration data were obtained by interpolating
the quadratic standard curve.
2.9. Statistic Analysis
Data were statistically evaluated using the statistical package GraphPad Prism 6.00
(San Diego, CA, USA), with independent or paired two-tailed samples t-tests, one-way ANOVA
followed by post hoc tests (see figure legends). All data were expressed as mean ± s.e.m. of the
determinations performed, and significance was set at p < 0.05. Experiments were repeated at least
three times. In pharmacological experiments, cell culture samples were allocated to groups randomly,
organizing the treatments on multi-well device. Graphs were created with GraphPad Prism 6.00.
3. Results
3.1. PKCε is Constitutively Expressed in PNS Cells and Tissue
We first characterized PKCε expression in isolated DRG neurons and SCs in vitro. We found that
PKCε is constitutively expressed by both cell types in vitro, observing higher PKCε gene expression in
cultured rat DRG neurons, than in SCs (Figure 1a). IFL images confirmed that the PKCε protein was
present both in DRG neurons (Figure 1b, upper panels; images in two z-axis optical sections) and SCs
(Figure 1b, lower panels); specificity was assessed by co-labeling with SMI32 (for high-density NF) and
s100, markers of DRG neurons and SC, respectively. These images showed that the phosphorylated
form of PKCε is evenly distributed throughout the cytoplasm (Figure 1b), both in neuronal soma and
SC, as well in neuronal arborization. Moreover, IFL showed localization of PKCε along unmyelinated as
well as myelinated fibers. Double-labelling of teased fibers with PKCε and SMI32 showed the presence
of phosphorylated and non-phosphorylated PKCε in unmyelinated axons (Figure 1c magnification
upper panel), and in surrounding non-myelinating SCs (Figure 1c; magnification lower panel).
Furthermore, myelinating SCs were immunopositive for PKCε (Figure 1c, magnification lower panel).
These observations were further confirmed in cross sections of the sciatic nerve, in which PKCε is
clearly present in unmyelinated axons and in surrounding SCs (Figure 1d, magnification 1), as well as
in myelinating SCs (Figure 1d, magnification 2, 3, 4). Cross sections allowed us to detect a subset of
myelinated fibers with PKCε also inside axons (Figure 1c, magnification 3 and 4), and in particular in
small diameter fibers (Figure 1d, magnification 4).
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Figure 1. PKCε characterization in PNS. (a) qRT-PCR analysis confirmed the presence of PKCε in DRG
neurons and SC primary cultures. Expression is normalized to the geometric mean of housekeeping
genes and presented as fold change relative to the mean expression value for DRG neurons. (b) IFL
analysis demonstrated the presence of the active/phosphorylated form of PKCε in DRG neuronal soma
and arborization as well as in SCs primary cultures. Upper panels for DRG neurons (images refer to two
z-axis optical sections): neurofilament marker SMI32 in red, p-PKCε immunopositivity in green and
DAPI in blue; merge images show co-localization (in yellow). Lower panels for SC: s100 in red, p-PKCε
in green and DAPI in blue; merge images show co-localization (in yellow). Bar: 30 µm. (c) Co-labeling
of PKCε (green) and neurofilament marker SMI32 (red), coupled with morphology observation of
myelinated and unmyelinated fibers, demonstrated that unmyelinated axons express PKCε (yellow
signal and absence of myelin structure), and confirmed the presence of PKCε in SCs (green signal and
typical myelin structure). (d) These observations were confirmed in coronal section of sciatic nerve
(see also magnifications in right panels). Myelinating and unmyelinating SCs express PKCε in their
cytosol and membrane (magnification 1 and 2 in green). Unmyelinated axons were immunopositive
for PKCε (magnification 1). A subpopulation of myelinated axons were immunopositive for PKCε
(magnification 3 in yellow), and in particular small diameter myelinated fibers (magnification 4 in
yellow). DAPI in blue. Bars in panels c and d are 20 µm; magnifications in panels c, bars are 20 µm;
magnifications 1, 2, 3, 4 in panel d, bars are 3 µm.
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3.2. Neuronal PKCε Is Regulated by an SC’s Humoral Factor
It is know that SCs synthesize the progesterone metabolite ALLO, one of the most important
mediator of neuron-glia interaction in peripheral nerves [6–9]. By means of HPLC-MS analysis, we
show here unequivocally the presence of ALLO 0.68 pg/µL (2.13 ± 0.95 nM) in the cytosol of SCs
(Figure 2b). ALLO 0.23 pg/µL (0.72 ± 0.43 nM) was also detected in Krebs-Ringer buffer exposed to
cultured SCs for 6 h, under a basal culture condition (Figure 2c). This finding confirmed that SCs
release ALLO physiologically. Based on this observation, we further investigated whether ALLO might
modulate PKCε expression in DRG neurons in vitro, confirming previous preliminary data already
published [28]. After 24 h treatment with ALLO at 1 µM, the PKCε expression in DRG neurons was
unaltered (Figure 2e). However, when the conditioned medium (CM) harvested from SCs, treated
for 24 h with ALLO 1 µM, was applied to DRG neuronal cultures for another 24 h, the PKCε gene
expression was significantly (p < 0.01) increased (Figure 2f), suggesting that a humoral mediator of
glia-to-neuron cross-talk was able to regulate PKCε. IFL analysis corroborated these data, showing that
PKCε protein was increased in DRG neurons exposed to the CM from ALLO-treated SCs (Figure 2g).
Images from two z-axis optical sections, indeed, showed p-PKCε immunopositivity increase (green)
both in neuronal soma and arborization (labeled with neurofilament marker SMI32 in red; Figure 2g).
Figure 2. ALLO is released by SCs and modulates neuronal PKCε. LC-MS/MS analysis of SCs cytosol
and KREBS buffer from 6 h-cultured SCs demonstrated the presence of ALLO. Multiple reaction
monitoring (MRM) traces of (a) blank sample (b) cytosolic fraction (c) medium fraction and (d) internal
standard, 13C-pregnenolone (PREG-20, 21-13C2; 10 ng/sample). Arrows indicate relative retention time
of ALLO (RT: 31.01–39.63; SM: 11G; m/z = 158.50 − 159.50 + 172.50 − 173.50 + 212.50 − 213.50 + 226.50 −
227.50; F:ITMS + cAPCI corona sid = 15.00; w Full ms2 [80.00–330]). (e) DRG neurons directly treated
with ALLO (1 µM) did not show PKCε expression modulation (CTRL n = 15, ALLO n = 8; p = 0.6284.
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The experiment was repeated four times. Data are mean ± s.e.m.). (f) PKCε expression was affected in
DRG neurons by ALLO-treated SC’s conditioned medium (CM + ALLO), showing an upregulation in
qRT-PCR, compared to ethanol-treated SC’s conditioned medium (CM CTRL), (p = 0.0040, t = 3.248,
CM CTRL n = 15, CM + ALLO n = 7 unpaired Student t-test. The experiment was repeated three times.
Data are mean ± s.e.m.; ** p < 0.01) (g) IFL analysis confirmed the increase in PKCε signal intensity in
both soma (z: two axes optical section) and arborization (z: one axis optical section) of DRG neurons
treated with CM + ALLO, compared with controls (CM CTRL), respectively; neurofilament marker
SMI32 in red, p-PKCε in green, DAPI in blue, merge co-localization in yellow. Bar: 30 µm.
3.3. ALLO Regulates the Production and Release of BDNF by SCs
To identify the mediator responsible for the CM-induced effect in DRG neurons, we focused
our attention on the growth factor BDNF, which was previously shown to be released by activated
SCs [33,34]. Exposure of SC cultures to ALLO 1 µM showed a significant elevation of BDNF expression
after 24 but not 2 h (Figure 3a; p < 0.05). Accordingly, both precursors (proBDNF) and mature
(mBDNF) BDNF protein levels increased significantly (Figure 3b; p < 0.05). The level of BDNF in 24-h
conditioned medium from SCs was measured by ELISA assay, resulting in 52.32 pg/mL (1.7 ± 0.39 pM)
concentration (Figure 3c). Treating cultured DRG neurons for 24 h with SCs’ CM + ALLO we found an
upregulation of the high affinity BDNF receptor trkB, corroborating the hypothesis of a BDNF-related
mechanism (Figure 3d; p < 0.01). IFL confirmed trkB activation (in green) in DRG neurons (positive
for the neurofilament marker SMI32 in red) after CM + ALLO treatment, with evidence of receptor
translocation to the cell membrane detected at z: two axes optical section (Figure 3e). Furthermore,
as shown in Figure 3e (at two z-axis optical sections) SCs’ CM effect on trkB activation was completely
blocked by the co-treatment with the specific trkB antagonist cyclotraxin-B (CYCLO) [35].
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Figure 3. BDNF is the neuron-glia mediator responsible of PKCεmodulation in DRG neurons. (a) SCs
treated with ALLO 1 µM for 24 h showed BDNF expression upregulation (p = 0.0034, t = 3.52, n = 14
unpaired Student t-test; the experiment was repeated four times; data are mean ± s.e.m.; ** p < 0.01) (b)
Western blot analysis that demonstrated upregulation of proBDNF (p = 0.033, t = 2.42, n = 12, unpaired
Student t-test) and mature BDNF (mBDNF; p = 0.046, t = 2.20, n = 13, unpaired Student t-test; the
experiment was repeated three times; data are mean ± s.e.m. of protein levels; * p < 0.05). (c) ELISA
assay on conditioned medium (CM + ALLO) from SCs (SCs treated 24-h with ALLO 1 µM) showed a
BDNF concentration of 1.7 ± 0.39 pM (n = 5 ± s.d.). (d) DRG neurons treated with SCs conditioned
medium (CM + ALLO) showed an upregulation of trkB receptor expression (p = 0.0012, t = 3.556,
unpaired t test; CM CTRL n = 21, CM + ALLO n = 12; the experiment was repeated four times; data are
mean ± s.e.m.; ** p < 0.01). (e) Confocal images (at two z-axis optical sections) showed trkB translocation
in cell membrane (z:2) after ALLO-treated SC conditioned medium (CM + ALLO), compared to control
treatment (CM CTRL). The CM + ALLO added with the specific trkB antagonist CYCLO (CM + ALLO
+ CYCLO) did not induce any trkB translocation in neuronal membrane; neurofilament marker SMI32
in red, trkB in green, DAPI in blue, merge co-localization in yellow. Bar: 30 µm.
Cells 2020, 9, 1874 10 of 17
3.4. BDNF Regulates PKCε in DRG Neurons Via trkB Activation
To replicate the effects of CM + ALLO on PKCε levels in DRG neurons, we treated these cells with
human recombinant BDNF, at 1 pM and 1 nM, respectively. Both BDNF concentrations significantly
upregulated PKCε gene expression (p < 0.05) after 24-h exposure (Figure 4a). IFL analysis highlighted
the additional effect of BDNF (Figure 4d), showing translocation of the phosphorylated form of p-PKCε
(green; at z: two axes optical section) to the membrane of DRG neurons (positive for SMI32 in red),
treated transiently (30 s) with BDNF 1 pM (Figure 4b). Then, we tested whether BDNF was affecting
neuronal PKCε expression via its classic receptor trkB. In support of a specific role of the trkB receptor,
DRG neurons were co-treated with BDNF 1 nM and the trkB specific antagonist CYCLO. qRT-PCR
analysis showed that CYCLO 10 nM was able to completely block PKCε upregulation induced by BDNF
(Figure 4c). Equally, CYCLO 10 nM completely blocked the effect of SCs’ CM on PKCε expression
(Figure 4d), as well as the p-PKCε rise in immunopositivity (Figure 4e, compared to Figure 2g),
indicating that the antagonist was blocking the effect of endogenous BDNF present in the CM. As a
control, the inactive form of CYCLO (TE) did not reverse the CM effect, confirming the specificity
of the trkB antagonist (Figure 4c). Overall, we demonstrated that secondary to ALLO release, SCs
increased BDNF, which upon secretion led to trkB-mediated upregulation of PKCε in DRG neurons.
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Figure 4. Glial BDNF modulates PNCε expression via trkB and induces its activation. (a) ALLO-treated
SCs’ CM effect has been mimicked by exogenous human recombinant BDNF treatment (one-way
ANOVA, p = 0.0278, F = 3.954; Brown-Forsythe test p = 0.0314, F (2.37) = 3.804; n = 40; Unpaired
t-test CTRL vs. BDNF 10−9 M, p = 0.0186, t = 2.517, df = 25. Unpaired t test CTRL vs. BDNF 10−12
M, p = 0.0105, t = 2.775, df = 24. The experiment was repeated four times. Data are mean ± s.e.m.;
* p < 0.05). (b) Confocal images (at two z-axis optical sections) showed that exogenous BDNF (1 pM)
treatment caused a fast PKCε reorganization in DRG neurons, moving active-p-PKCε in the membrane
(z:2). Neurofilament marker SMI32 in red, p-PKCε in green, DAPI in blue, merge co-localization in
yellow. Bar: 30 µm. (c) PKCεmodulation mediated by exogenous BDNF was blocked by specific trkB
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antagonist CYCLO (one-way ANOVA p = 0.0016, F = 7.972; Brown-Forsthe test p = 0.0017,
F (2.31) = 7.909; n = 34; Tukey’s multiple comparison test CTRL vs. BDNF 10−9 M p = 0.0115,
q = 4.362; BDNF 10−9 M vs. BDNF 10−9 M + CYCLO p = 0.0023, q = 5.240. The experiment was repeated
three times. Data are mean ± s.e.m.; * p < 0.05, ** p < 0.01). (d) CYCLO treatment is also able to block
CM + ALLO action on DRG neurons (one-way ANOVA p = 0.0024, Bartlett’s test p = 0.0252; n = 49;
Tukey’s multiple comparison test CM CTRL vs. CM + ALLO p = 0.0054; CM CTRL vs. CM + ALLO +
CYCLO p = 0.9507; CM CTRL vs. CM + ALLO +TE p = 0.0307. The experiment was repeated three
times. Data are mean ± s.e.m.; * p < 0.05, ** p < 0.01). (e) IFL confirmed that CYCLO 10 nM blocked the
effect of SCs’ CM + ALLO increase in p-PKCε immunopositivity (see Figure 2g), lowering back to the
levels detected in control (CM CTRL). Neurofilament marker SMI32 in red, p-PKCε in green, DAPI in
blue, merge co-localization in yellow. Bar: 30 µm.
4. Discussion
Our experiments demonstrated that ALLO promoted SC-dependent activation of a signaling
cascade, involving BDNF release and neuronal PKCε upregulation. In detail, we found that SCs
tonically release ALLO, which in turn upregulates the synthesis and release of BDNF in an autocrine
fashion. Subsequently, BDNF controls PKCε in DRG sensory neurons, via trkB activation in paracrine
manner (Figure 5).
Figure 5. Schematic representation of neuron-glia cross talk in peripheral fibers. (a) SCs possess the
enzymatic machinery to synthetize ALLO [9], (b) and tonically release it in vitro. (c) ALLO increases
BDNF expression, and (d) its protein levels in SCs. (e) BDNF is released by SCs and activates neuronal
trkB. (f) TrkB mediates the upregulation of PKCε expression in DRG neurons (g) and a simultaneous
PKCε activation consisting in its phosphorylation and translocation to neuronal membrane. (h) PKCε
is renown to increase neuronal excitability via the phosphorylation of several ion channels, likely
promoting hyperalgesic priming of peripheral fibers [19]. (i) leading to the modulation of noxious
stimuli to the CNS.
This line of evidence is consistent with the predominance of the local interaction, in the PNS,
between SCs and peripheral sensory neurons. Beyond their myelinating activity, SCs exert a crucial
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role on neuronal functions, strengthening their importance in glia-to-neuron crosstalk. Although
these effects occur in the microdomain of SCs-axon, they may reflect on the neuronal soma, likely
DRG neurons, given that the retrograde transport of molecules and proteins along axons was widely
demonstrated in the PNS [36,37]. Moreover, it was proven that SCs-derived neurotrophic factors are
transported anterogradely as well as retrogradely within peripheral neurons [38].
We found that SCs are capable of ALLO synthesis and its tonic release under physiological
conditions. Notably, ALLO synthesized by SCs might attain efficient concentration in the narrow space
between SC membrane and axon, both in myelinated fibers (i.e., in the periaxonal/adaxonal space) and
in unmyelinated fibers (i.e., Remak bundles). The observation that ALLO serves as an autocrine factor in
SCs is not new, since it was already demonstrated that ALLO enhances the glutamic acid decarboxylase
(GAD) expression/activity and subsequently GABA synthesis in SCs [13,15]. Interestingly, ALLO has
been proposed as a possible pharmacological treatment for nerve degenerative diseases [10,11,14,15,39]
and hyperalgesia [39]. Nerve regeneration, occurring after peripheral nerve damage, is generally
associated with hypersensitivity and possible development of chronic pathological pain states [40].
A similar phenomenon has been observed for neurotrophins, which proved to be potent modulators of
neuroregeneration and neuronal plasticity [41], within a concomitant increase in excitability. In the
CNS, BDNF has been reported to enhance neuronal excitability [42], promoting neurotransmitter
release [43], to phosphorylate specific glutamate receptor subunits [44,45] and to modulate ion channel
conductance [46]. Similarly, in the PNS, BDNF expression in DRGs is markedly increased by injury or
inflammation [47–49] whereas trkB activation promotes synaptic plasticity in the dorsal horn [47].
The ALLO-induced BDNF synthesis and release have been previously demonstrated in the
CNS [50]. Herein, we suggest that in the PNS, the increase of ALLO and consequent rise of BDNF local
release might entail a dualistic effect on nerves. This promotes regeneration and acute control of pain,
likely triggering the activation of an intracellular cascade that induces a long-term sensitization of
neurons, thus priming peripheral nociceptors [19,20].
BDNF as well as trkB receptor expression in a distinct subset of peripheral sensory neurons have
been well characterized. Indeed, by means of electrophysiological techniques [51,52] and single-cell
sequencing approaches [52–54], their expression was highlighted in low threshold mechanosensitive A
delta fibers [55], and in a small subset of C-nociceptors [56–58]. In accordance, trkB specific expression
in these peripheral nociceptors provides a pathway through which SC derived BDNF can regulate
neuropathic pain. Likewise, we found that PKCε is expressed in thinly myelinated fibers (low threshold
mechanosensitive A delta) and unmyelinated fibers (C-nociceptors), supporting the interaction between
peripheral trkB and PKCε. Generally, the A delta and C fibers increase in excitability leads to allodynia
and hyperalgesia, respectively.
PKCε presence in sensory neurons is consistent with previous observation in vivo, showing its
activation in rat lumbar DRG neurons during inflammatory and neuropathic pain [59]. Interestingly,
PKCε activation in DRG sensory neurons is likely to be associated with its capacity for ion channel
phosphorylation. PKCε increases the open probability of TRPV1 [21,22], decreases GABAA-R membrane
trafficking [23,24] and upregulates Nav1.8 expression [26]. In particular, it should be highlighted
that PKCε promotes GABAA-R desensitization. Namely, PKCε phosphorylates the γ2 subunit of
GABAA-R, reducing its responsivity to specific allosteric agonists [27]. Moreover, PKCε regulates
GABAA-R trafficking, decreasing its cell surface expression and GABA currents [24]. Such a specific
interaction between PKCε and GABAA-R might partially explain the non-canonical role of ALLO
on pain modulation. ALLO can indeed potentiate GABAA-R currents acutely, acting as an allosteric
modulator [39], but in chronic conditions it could lead to the release of BDNF and thus PKCε activation,
eliciting an opposite effect and inducing hypersensitivity.
In conclusion, we provide consistent evidence that SCs are a peripheral local source for the
neuroactive steroid ALLO, which leads to BDNF release and paracrine PKCε upregulation, via neuronal
trkB activation. However, further studies are required to characterize the physio-pathological responses
occurring in DRG sensory neurons following PKCε activation. We suggest that further characterization
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of these molecular mechanisms of glia-to-neuron interaction may foster our understanding of
neuropathic pain etiology, helping to identify novel targets for pharmacological treatments.
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cultures; bars: 30 µm, Supplementary Figure S3: CSLM z stack images comparing medium diameter DRG neurons
(z = 9 µm) vs. small diameter DRG neurons (z = 4 µm); bars: 10 µm.
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